GCM
VNDA icon

Graham Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Graham Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,060
Closed -$203K – 1536
2025
Q4 		$203K Buy
+23,060
New +$127K ﹤0.01% 1038
2024
Q2 		– Sell
-27,045
Closed -$111K – 1390
2024
Q1 		$111K Buy
27,045
+1,703
+7% +$6.82K ﹤0.01% 964
2023
Q4 		$107K Buy
+25,342
New +$102K ﹤0.01% 905

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's VNDA Position: Q1 2026 in Review

Graham Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 23,060 shares — an estimated $203K sold.

Graham Capital Management first reported a position in VNDA in Q4 2023 and held it in 3 quarters. The position peaked at $203K in Q4 2025. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Graham Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 23,060 Vanda Pharmaceuticals shares in Q1 2026, an estimated $203K.
  • Graham Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Graham Capital Management's Vanda Pharmaceuticals position peaked at $203K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.